In that game, Walker had 67 rushing yards, three receptions for 44 yards and a touchdown. Macdonald added, "It just shows you ...

Company to submit Investigational Device Exemption (IDE) to FDA for novel CBGM technology in Spring 2026 Expanded clinical advisory team with appointment of pain management and medical technology ...

PALO ALTO, Calif., Nov. 13, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the third quarter ended September 30, 2025.

- Closed registered direct offering for aggregate gross proceeds of US$175 million (the “Registered Direct Offering”) led by a syndicate of prominent biopharmaceutical institutional investors - - On ...

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced third quarter ...

CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $524 million EC and U.S. FDA label updates for CARVYKTI ® to include overall survival benefit versus standard of care ...

– Successful outcome from FDA meeting on ALTO-207 in treatment-resistant depression; on track to initiate Phase 2b trial in the first half of 2026 and Phase 3 trial by early 2027 – – Positive blinded ...

– FREEDOM-DM1 15 mg/kg cohort demonstrated the highest mean splicing correction reported to date in DM1 patients – – FREEDOM2-DM1 5 mg/kg cohort on track to readout in Q1 2026, with all patients ...

– Topline data for Phase 2 trials of ALTO-101 in CIAS expected 1Q 2026 and ALTO-300 in MDD expected mid-2026 – – Closed $50 million PIPE; strong cash position of $184.2 million as of October 31 ...

So many celebrated the life of Hildy Morgan here at her beloved Dietrich Theater, her opus magnum or masterwork. We heard stories from colleagues and friends of her vision and undaunted determination ...